Concepedia

Khalid Lakhdari

KL

Statistics

Publications

4

Citations

127

H-Index

4

Active since

2019

Affiliations

Bristol-Myers Squibb (United States)(Current)

Bristol-Myers Squibb (Canada)

Bristol-Myers Squibb (United Kingdom)

PAREXEL International (United Kingdom)

Khalid Lakhdari is an author at Bristol-Myers Squibb (United States) specializing in oncology, non-small cell lung cancer treatment, and non-small cell lung cancer therapy.

Publications per year

2019–2022

4

Publications

4

Evaluating Partitioned Survival and Markov Decision-Analytic Modeling Approaches for Use in Cost-Effectiveness Analysis: Estimating and Comparing Survival Outcomes

Caitlin Smare, Khalid Lakhdari, Justin Doan et al. · PharmacoEconomics · 2019 · 58 citations · Full text

, , +17

Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis

Robert Carroll, Margherita Bortolini, Alan Calleja et al. · BMC Cancer · 2022 · 28 citations · Full text

, , +12

Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada

D. Debieuvre, Rosalyn A. Juergens, Bernard Asselain et al. · Lung Cancer · 2021 · 23 citations · Full text

, , +17

Cost-effectiveness of nivolumab in squamous and non-squamous non-small cell lung cancer in Canada and Sweden: an update with 5-year data

Mohammad A. Chaudhary, Christoffer Holmberg, Khalid Lakhdari et al. · Journal of Medical Economics · 2021 · 18 citations · Full text

, , +17

1–4 of 4